United Therapeutics breakthrough PAH/IPF data point to revenue doubling

 

United Therapeutics posts solid Q1 as breakthrough PAH/IPF data point to revenue doubling

• Q1 2026 non-GAAP EPS $5.82 (-12% YoY) and revenue $781.5M (-2% YoY), both came in below estimates.
• Authorized $2.0B share repurchase program, including a $1.5B accelerated buyback component announced with earnings release.
• Q1 2026 net income totaled $274.9 million, according to the company's latest earnings announcement.
• Q1 revenue $782M; seasonality, winter storms and pharmacy issues temporarily dampened February sales.
• Tyvaso revenue $458M, up 9% YoY, driven by strong Tyvaso DPI patient demand.
• Management expects return to sequential growth near term and sustained double-digit long-term revenue growth.
• Ralinepag OUTCOMES Phase III showed roughly threefold reduction in PAH disease progression versus background therapy.
• Company expects ralinepag to double treated PAH patients to over 30,000 within two years post-launch.
• Management believes ralinepag and Tyvaso IPF each can exceed today’s ~$3B revenue run rate individually.
• Supplemental NDA for nebulized Tyvaso in IPF planned by late summer; possible launch by Q2 2027.
• Oral ralinepag targeted for mid-2027 launch; inhaled ralinepag DPI entering Phase I this year.
• EPS, margins, cash flow, and detailed 2026 financial guidance were not disclosed on this call.
• Main risks are competitive inhaled prostacyclin market plus execution and regulatory outcomes for multiple launches.
• Main concern: execution and regulatory risks around multiple high-impact PAH and IPF launches.
• Strong quarter, driven by breakthrough PAH/IPF trial results and resilient Tyvaso DPI demand.

https://finviz.com/quote?t=UTHR&p=d